TAK-079 is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.

SparkCures ID 310
Developed By Takeda Oncology
Generic Name TAK-079
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Takeda Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners